FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> vaccine recall | Intercell
Syndicate content

Intercell recalls encephalitis vaccine batch

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

Austria-based vaccine maker Intercell has recalled a batch of its Japanese encephalitis vaccine Ixiaro in the European Union. The drugmaker says some vaccines at the end of their shelf life lacked potency, and said that those who'd received the shot may want to get vaccinated again. Overall, about 5,000 doses of the vaccine were recalled in Britain, France, Italy and Spain.

Intercell CEO Thomas Lingelbach said the recall is an isolated incident and is not indicative of larger problems in the vaccine's manufacturing. "The total cost to Intercell (of the recall) will be below €100,000 ($142,000) so we will not even see that on the balance sheet," he told Reuters. "This is indeed a real non-issue and why the markets overreact to it, I do not know...There is no systemic issue or problem with the product. This is a pure precautionary measure." Lingelbach replaced former CEO Gerd Zettlmeissl earlier this month after the vaccine developer's experimental patch for travelers' diarrhea flunked two late-stage trials.

Ixiaro is Intercell's only marketed product. The company is aiming for 60-70 percent growth in 2011 sales of the vaccine based on interest from the U.S. military and those traveling abroad.

- check out the Reuters report

Related Articles:
Struggling Intercell replaces its CEO
Intercell shares nosedive as investigators slam brakes on patient recruitment
Panel recommends Intercell's new Japanese encephalitis jab


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about vaccine recall   Intercell  

Comments

Post a comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.